PM receives major grant “CHAIMELEON” from EC on AI for medical images

PM receives major grant “CHAIMELEON” from EC on AI for medical images

More: The Dpt of Precision Medicine received the EC hrqnt titled “Accelerating the lab to market transition of AI tools for cancer management” (call: Trusted digital solutions and Cybersecurity in Health and Care: H2020-SC1-FA-DTS-2018-2020; total grant amount: 8.784.039 Euro , part of rPrecision medicine: 578.312 Euro:

CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. An EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries. It will build on partner´s experience (e.g. PRIMAGE repository for paediatric cancer and the Euro-BioImaging node for Valencia population, by HULAFE; the Radiomics Imaging Archive by Maastricht University; the national repository DRIM AI France, the Oncology imaging biobank by Pisa University). Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed lung, prostate and colorectal cancer patients. A multimodal analytical data engine will facilitate to interpret, extract and exploit the right information stored at the Repository. An ambitious development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and images harmonisation, the latest being of the highest importance for enabling reproducibility of Radiomics when using large multiscanner/multicentre image datasets. The usability and performance of the Repository as a tool fostering AI experimentation will be validated, including a validation subphase by other world-class European AI developers, articulated via the organisation of Open Challenges to the AI Community. A set of selected AI tools will undergo early on-silico validation in observational (non-interventional) clinical studies coordinated by leading experts in Gustave Roussy (lung cancer), San Donato (breast), Sapienza (colorectal) and La Fe (prostate) hospitals. Their performance will be assessed, including external independent validation, on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer.

Spain

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA

COMUNIDAD VALENCIANA

Italy

UNIVERSITA DI PISA IT

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

POLICLINICO SAN DONATO SPA

Portugal

CENTRO HOSPITALAR UNIVERSITARIO DO PORTO EPE

France

CERF – College des Enseignants en Radiologie de France

MEDEXPRIM

The Netherlands

UNIVERSITEIT MAASTRICHT

Germany

CHARITE – UNIVERSITAETSMEDIZIN BERLIN

GE HEALTHCARE GMBH – GEHC

United Kingdom

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Israel

BEN-GURION UNIVERSITY OF THE NEGEV

Spain

UNIVERSITAT POLITECNICA DE VALENCIA

QUIBIM SOCIEDAD LIMITADA

BAHIA SOFTWARE SL

MATICAL INNOVATION SL

UNIVERSITAT DE VALENCIA ES

Austria

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER

BIOMEDIZINISCHEN BILDGEBUNG


 

BUY NOW